Changes in Hong Kong stocks | Yingpai Pharmaceutical-B (07630) rose more than 20% at the end of the session. The company entered the Hong Kong Stock Connect list this week and quickly released Senapali after enrolling in health insurance

The Zhitong Finance App learned that Yingpai Pharmaceutical-B (07630) rose more than 20% at the end of the session. As of press release, it rose 19.97% to HK$13.94, with a turnover of HK$82.4778 million.

According to the news, Yingpai Pharmaceutical revealed on September 3 that Dr. Choi Suixiong, the executive director and CEO, has increased the company's common stock holdings by 100,000 shares in the open market. Dr. Choi said he is confident in the Group's overall fundamentals, development prospects and potential growth. Furthermore, since September 7, Yingpai Pharmaceutical was included in the list of eligible securities of Shanghai-Hong Kong Stock Connect and Shenzhen-Hong Kong Stock Connect, and was included as a component stock of the Hang Seng Composite Index on the same day.

According to public information, Yingpai Pharmaceutical's core product, senapalil (PARP1/2 inhibitor), has been included in national health insurance since 2026. 2026H1 China's sales revenue was 70 million yuan, an increase of 877.8% over the previous year. As of June 30, 2026, Senapali has covered all provinces in mainland China, admitted more than 380 specialty and community pharmacies, and covered nearly 1,200 medical institutions.